Aber superflach,Kadmon,Andreano ! Wo seid ihr ?? Habt ihr etwa geschmissen ?!? Oder alles mit HTOG rumverzockt ?
Was Vermeer,wir beide hatten einfach das richtige "Feeling" für Atherogenics,hatten uns ja noch vor kurzem über BM unterhalten.Das angängige Nasdaq-Delisting Prozedere dürfte nach angestrebter anhörung wohl wieder rückgängig gemacht werden,was meinst du ? Wir notieren ja bereits über ein dollar und damit ist "AlLes klar"!
Hier noch mal zum geniessen:
7:10AM AtheroGenics announces top-line results from its ANDES Phase 3 clinical trial; both doses of AGI-1067 met the primary efficacy endpoint (AGIX) 0.55 : Co announced top-line results from its ANDES Phase 3 clinical trial of AGI-1067 (succinobucol) for the treatment of Type 2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen. "We are pleased that the ANDES trial met the primary endpoint and showed a dose response in reducing A1c. Based on the results of this successful trial, AtheroGenics intends to rapidly move forward with development of AGI-1067... We believe that AGI-1067, through its unique mechanism of action, could become the first diabetes treatment with demonstrated cardiovascular safety, and with the potential to reduce cardiovascular hard events including cardiovascular death, heart attack and stroke, as reported from the 6,144 patient Phase 3 ARISE trial, which concluded in 2007."
HAMMER -- HAMMER -- HAMMER !!! GO AGIX GO !!!
MFG Chali
|